4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-22-011841
Options or other derivatives
- Chief Financial Officer acquired 45,300 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| Smith Brendan Chief Financial Officer | 2022-02-18 | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | D | ||
| Smith Brendan Chief Financial Officer | 2022-02-18 | Grant or award · Restricted Stock Units | +15,300 | 15,300 | D | ||
Loading xslF345X03/doc4.xml…